On May 8, 2024, Clinomics Inc. closed the transaction. The company announced that it has issued 3% Series 3 Bearer-Type Non-Guaranteed Private Placement Convertible Bond due May 8, 2027 for the gross proceeds of KRW 12,000,000,000 in its second tranche.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,398 KRW | -2.71% | -8.03% | -45.50% |
May. 17 | Clinomics Inc. announced that it has received KRW 4 billion in funding | CI |
May. 14 | Clinomics Inc. announced that it expects to receive KRW 4 billion in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-45.50% | 39.66M | |
+23.50% | 47.07B | |
+47.70% | 42.06B | |
-5.16% | 39.98B | |
+36.37% | 33.02B | |
-7.79% | 27.9B | |
+18.06% | 27.63B | |
+47.29% | 14.37B | |
+41.91% | 13.45B | |
-1.02% | 12.03B |
- Stock Market
- Equities
- A352770 Stock
- News Clinomics Inc.
- Clinomics Inc. announced that it has received KRW 32.600017466 billion in funding from Cdbio Co., Ltd., Daon Engineering Co., Ltd, Baro Savings Bank, The Korea Securities Finance Corporation